Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Chiarle

Showing results (121-130 of 156) with videos related to

Pageof 16
Sort By:
Blood|October 17, 2021
Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphomaElif Karaca Atabay, Carmen Mecca, Qi Wang, et al.
Cancer Cell|December 1, 2023
ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cellsElisa Bergaggio, Wei-Tien Tai, Andrea Aroldi, et al.
Leukemia|April 2, 2025
HDAC1 acts as a tumor suppressor in ALK-positive anaplastic large cell lymphoma: implications for HDAC inhibitor therapyMaša Zrimšek, Kristina Draganić, Anna Malzer, et al.
Elife|March 18, 2016
Hepatocyte Growth Factor-mediated satellite cells niche perturbation promotes development of distinct sarcoma subtypesDeborah Morena, Nicola Maestro, Francesca Bersani, et al.
JTO Clinical and Research Reports|December 23, 2022
Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain MetastasesMarcin Nicoś, Luuk Harbers, Enrico Patrucco, et al.
Nature|February 16, 2017
Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cellsMara Compagno, Qi Wang, Chiara Pighi, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 15, 2018
Parp3 promotes long-range end joining in murine cellsJacob V Layer, J Patrick Cleary, Alexander J Brown, et al.
Cancer Discovery|June 22, 2026
EML4-ALK mediates resistance to KRAS G12C inhibition and induces an oncogenic dependency by rewiring signaling through the wild-type RAS pathwayPietro Scaparone, Alessia Mira, Taek-Chin Cheong, et al.
Cancer Immunology Research|October 1, 2015
Efficacy of a Cancer Vaccine against ALK-Rearranged Lung TumorsClaudia Voena, Matteo Menotti, Cristina Mastini, et al.
The Lancet. Oncology|September 13, 2024
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trialAlessandra Tedeschi, Anna Maria Frustaci, Adalgisa Condoluci, et al.
Pageof 16

Showing results (121-130 of 156) with videos related to

Sort By:
Pageof 16
Blood|October 17, 2021
Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphomaElif Karaca Atabay, Carmen Mecca, Qi Wang, et al.
Cancer Cell|December 1, 2023
ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cellsElisa Bergaggio, Wei-Tien Tai, Andrea Aroldi, et al.
Leukemia|April 2, 2025
HDAC1 acts as a tumor suppressor in ALK-positive anaplastic large cell lymphoma: implications for HDAC inhibitor therapyMaša Zrimšek, Kristina Draganić, Anna Malzer, et al.
Elife|March 18, 2016
Hepatocyte Growth Factor-mediated satellite cells niche perturbation promotes development of distinct sarcoma subtypesDeborah Morena, Nicola Maestro, Francesca Bersani, et al.
JTO Clinical and Research Reports|December 23, 2022
Genomic Profiling Identifies Putative Pathogenic Alterations in NSCLC Brain MetastasesMarcin Nicoś, Luuk Harbers, Enrico Patrucco, et al.
Nature|February 16, 2017
Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cellsMara Compagno, Qi Wang, Chiara Pighi, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 15, 2018
Parp3 promotes long-range end joining in murine cellsJacob V Layer, J Patrick Cleary, Alexander J Brown, et al.
Cancer Discovery|June 22, 2026
EML4-ALK mediates resistance to KRAS G12C inhibition and induces an oncogenic dependency by rewiring signaling through the wild-type RAS pathwayPietro Scaparone, Alessia Mira, Taek-Chin Cheong, et al.
Cancer Immunology Research|October 1, 2015
Efficacy of a Cancer Vaccine against ALK-Rearranged Lung TumorsClaudia Voena, Matteo Menotti, Cristina Mastini, et al.
The Lancet. Oncology|September 13, 2024
Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trialAlessandra Tedeschi, Anna Maria Frustaci, Adalgisa Condoluci, et al.
Pageof 16